RBC Capital Maintains Sector Perform on Pacira BioSciences, Raises Price Target to $25

Benzinga Newsdesk www.benzinga.com Positive 90.2%

Neg 0% Neu 0% Pos 90.2%

RBC Capital analyst Douglas Miehm maintains Pacira BioSciences (NASDAQ:PCRX) with a Sector Perform and raises the price target from $24 to $25.